Welcome back: Outsourcing in Clinical Trials New England 20131-2 October 2013, Boston, MA
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events.
We are proud to invite you to Arena International’s 5th annual Outsourcing in Clinical Trials New England conference – the flagship event of our entire series –and to actively get involved in what promises to be another exceptional event.
In October 2013, OCT New England will once again prove industry leadership in providing cutting-edge solutions and a phenomenal speaker faculty.
Building on last year’s roaring success, this year’s agenda has been compiled with the help of OCT New England Advisory Board, bringing unprecedented value to CROs, biotechnology and pharmaceutical companies alike.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Our agenda will present a varied yet balanced range of topics to ensure an in-depth but holistic overview of Outsourcing in Clinical Trials.
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events. Here are just 7 of the reasons to attend our most popular event series.
We are excited to announce that the Venue for OCT New England will be the Westin Boston Waterfront.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
We are proud to boast the following feedback from attendees at our Outsourcing Series:
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS).
US-based biopharmaceutical firm CytRx has released positive top-line efficacy results from a Phase IIb clinical trial, which evaluated the efficacy and safety of aldoxorubicin compared to doxorubicin in patients with first-line metastatic, locally ad…
Sunovion Pharmaceuticals has released results from a pooled analysis of three Phase III randomised, placebo-controlled trials (Studies 301, 302 and 304) assessing the safety and efficacy of once-daily Aptiom (eslicarbazepine acetate) as adjunctive tr…
US-based Verastem has started an open-label, dose escalation and schedule finding Phase I trial of a dual mTORC1/2 and PI3K inhibitor 'VS-5584' for treatment of patients with advanced solid tumours or lymphoma.
US-based biopharmaceutical firm Portola Pharmaceuticals has released additional results of a Phase II proof-of-concept trial of its investigational Factor Xa inhibitor antidote 'andexanet alfa (PRT4445)', in healthy volunteers who were administered t…
US-based biotechnology firm Gilead Sciences has released interim results of a single-arm, open-label Phase II study of its investigational oral inhibitor of spleen tyrosine kinase (Syk) GS-9973 for treatment of patients with relapsed or refractory ha…
US-based clinical stage biotechnology firm Catabasis Pharmaceuticals has started the second Phase II clinical trial to assess the safety and efficacy of CAT-2003 in patients with severe hypertriglyceridemia, defined as serum triglyceride levels of 50…